Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Transform Wealth LLC

Transform Wealth LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,900 shares of the pharmaceutical company’s stock after acquiring an additional 891 shares during the period. Transform Wealth LLC’s holdings in Vertex Pharmaceuticals were worth $10,027,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in VRTX. Crossmark Global Holdings Inc. raised its position in shares of Vertex Pharmaceuticals by 5.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 6,207 shares of the pharmaceutical company’s stock valued at $2,499,000 after buying an additional 341 shares during the last quarter. Sugar Maple Asset Management LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at about $35,000. Ballentine Partners LLC lifted its stake in Vertex Pharmaceuticals by 2.2% in the 4th quarter. Ballentine Partners LLC now owns 5,590 shares of the pharmaceutical company’s stock worth $2,251,000 after purchasing an additional 119 shares in the last quarter. Atwood & Palmer Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 2.1% during the 4th quarter. Atwood & Palmer Inc. now owns 55,390 shares of the pharmaceutical company’s stock worth $22,306,000 after purchasing an additional 1,130 shares during the last quarter. Finally, Koshinski Asset Management Inc. grew its position in shares of Vertex Pharmaceuticals by 3.4% in the fourth quarter. Koshinski Asset Management Inc. now owns 1,357 shares of the pharmaceutical company’s stock valued at $546,000 after purchasing an additional 45 shares in the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on VRTX shares. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Monday, January 13th. Scotiabank lifted their price target on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a report on Monday, December 23rd. Truist Financial dropped their price objective on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a report on Monday, December 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research note on Monday, December 23rd. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Trading Up 1.2 %

NASDAQ VRTX opened at $422.00 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $439.34 and a two-hundred day moving average of $465.72. The stock has a market capitalization of $108.68 billion, a PE ratio of -212.06, a price-to-earnings-growth ratio of 2.17 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.67 EPS. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.